US 12,295,949 B2
Treatment of the gastrointestinal tract with dimeric naphthalimide compounds
Barbara R. Haberer, Hartford, SD (US); and Ronald E. Utecht, Madison, SD (US)
Assigned to Alumend, LLC, Sioux Falls, SD (US)
Filed by Alumend, LLC, Sioux Falls, SD (US)
Filed on Nov. 14, 2022, as Appl. No. 17/986,350.
Claims priority of provisional application 63/395,854, filed on Aug. 7, 2022.
Prior Publication US 2024/0050425 A1, Feb. 15, 2024
Int. Cl. A61K 31/473 (2006.01); A61K 41/00 (2020.01); A61P 1/04 (2006.01)
CPC A61K 31/473 (2013.01) [A61K 41/0057 (2013.01); A61P 1/04 (2018.01)] 52 Claims
 
1. A method of inhibiting loss of an increased lumen in an area of stenosis of the digestive system following dilatation of the stenotic area in a subject, comprising administering to an area of the dilatation a composition comprising an effective amount of a dimeric naphthalimide, or a pharmaceutically acceptable salt thereof, and activating the dimeric naphthalimide via electromagnetic energy, wherein the dimeric naphthalimide is represented by any one of structures I, II and III:

OG Complex Work Unit Chemistry
wherein R, R′, and Q are each independently selected from the group consisting of straight-chain and branched chain alkyl groups having from 2 to 50 carbons, optionally substituted with one or more ether groups, one or more amide groups, or one or more amine groups; and wherein X is hydrogen, a halogen, a sulfonate ester or a quaternary ammonium salt.